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Abstract 
Background - Chronic hepatitis C virus infection is a massive worldwide healthcare burden 
with estimated costs in the USA alone of over $5 billon per annum. The only current 
effective treatment is combination therapy with interferon alpha and ribavirin (IFNα + RBV) 
which is expensive and has significant side-effects. Unfortunately, it is only effective in up to 
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50% of those infected with HCV genotype 1.  In this study the examination of the patterns for 
the protein expression followed the peg-IFNα + RBV treatment in patients whom were 
selected to demonstrate different durations of the disease depending upon their response. The 
current treatment usually gives an SVR rate of around 55 %. Through the virological and 
host-related factors, the predictive value of HCV kinetics during treatment seems to exceed 
that of all virus and host-related baseline factors for predicting the virologic response. The 
identification of easily measurable biomarkers which predict response to treatment either 
before or during the early stages would enable better selection of those who would benefit 
from starting or continuing treatment. The search for novel biomarkers in disease has been 
the focus of increased attention in recent years due to the advances made in proteomic 
technology. The plasma proteome is an attractive target for such studies because it is readily 
available from patients on a regular basis. It is also in contact with all tissues in the body and 
so may reveal differences in the abundance of proteins expressed in these tissues.  Current 
proteomic technology allows the characterisation of plasma proteins across a wide dynamic 
range to include those secreted from cells at relatively high concentration to those there due 
to tissue leakage present at extremely low levels. In this pilot study the plasma from a small 
number of selected patients was subjected to proteomic analysis to investigate whether there 
were variations in plasma protein profile which could predict treatment efficacy.   
AIMS - The article shows the first stages of an ongoing analysis of the plasma proteome. As 
the aim is to identifying the potential biomarkers which indicate either responsiveness or 
resistance to treatment of chronic HCV with interferon alpha and ribavirin. 
Methods - Three patients chronically infected with Hepatitis C virus genotype 1b who were 
to be treated with pegylated Interferon alpha and Ribavirin were selected for the pilot study. 
The total length of treatment was to be 48 weeks and patients were followed up as out-
patients where biochemical and virologic parameters were measured and used as indicators of 
response. 
Peripheral blood samples were taken into EDTA at the start of treatment and again at 14 and 
28 days. Blood was immediately cooled on ice and within 15 minutes centrifuged at 3000 
rpm for 10 minutes to separate the plasma which was aliquoted and stored at -80°C.  
The plasma was depleted of albumin and IgG using the Bio-Rad Aurum Serum protein mini 
kit. This method removed over 90% of the total albumin and immunoglobin, effectively 
enriching the other plasma proteins and maximising their resolution by electrophoresis. 
Protein concentration of the depleted plasma was estimated using the Bradford assay. 
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2D gel electrophoresis was performed on selected samples using GE Healthcare IPGphor IEF 
and Ettan units. Briefly, 70 µg depleted plasma protein was mixed with Sample Buffer (8M 
urea; 4% CHAPS; 2% Ampholytes; 50 mM DTT; 0.001% Pyronin Y) and rehydrated into 
immobilized pH Gradient (IPG) strips overnight (5-8 pH range). 
Isoelectric focusing was carried out. The IPG strips were then equilibrated into Loading 
Buffer (8M Urea; 50 mM Tris, 2% Lauryl SDS, 0.001% Pyronin Y, pH 6.8) and reduced with 
50 mM DTT, prior to alkylation with 20 mM iodoacetamide. The IPG strips were then run 
onto a 12% Polyacrylamide gel for SDS-PAGE. The gels were then washed briefly and 
stained with Colloidal Coomassie Blue. The gels were destained in water and imaged using a 
BioRad GS-800 Scanning Densitometer and PDQuest software. 
10 µg samples of plasma for 1D SDS-PAGE were added to four-times the volume of Loading 
Buffer. Samples were kept cool and then electrophoresed through a 12% SDS-PAGE gel. The 
gels were then either stained with Colloidal Blue or imaged, or electroblotted onto PVDF 
membrane. The membrane was blocked with 5% milk powder and then probed with mouse 
monoclonal antibody to human haptoglobin (Sigma H6395). The membrane was then washed 
thoroughly with PBS/Tween, incubated with antibody to mouse immunoglobulins-HRP 
(Dako P0260) and washed again with PBS/Tween. The membrane was developed using ECL 
plus (GE Healthcare) and the image acquired on a BioRad Fluor-S multi-imager.  
Spots and bands were excised from the polyacrylamide gels and dried under vacuum. 
Proteins were digested using trypsin in 30 mM Ammonium Bicarbonate. The samples were 
concentrated under vacuum and extracted using a mixture of acetonitrile and 0.1% Formic 
Acid. Peptides were separated and identified using electrospray mass spectrometry (LC-
MS/MS). The peptides of the mixture were separated using reverse-phase chromatography 
over a C18 column (Dionex) onto a Waters Q-ToF Micro. Tandem mass spectrometry data 
were analysed using the Mascot programme (Matrix Science).   
Results - A number of differences were seen in patients compared with controls when the 
plasma was analyzed using 2D electrophoresis. Perhaps the most striking being the absence 
of haptoglobin alpha chain forms which were identified by electrospray mass spectrometry 
(Fig 1). 
Further analysis of albumin-depleted plasma by 1D SDS-PAGE found that two of the patients 
showed a considerable increase in an approximately 80 kDa protein band in samples taken at 
days 14 and 28 on treatment when compared with a pre-treatment sample (Fig 2). 
This protein was identified as deriving from the haptoglobin precursor using LC-MS/MS, the 
patients who exhibited the increase in the ~80 kDa protein were a responder and a transient 
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responder to treatment. The patient who did not respond to treatment showed no temporal 
increase in this band. The increase in the 80 kDa form of haptoglobin in responders was 
confirmed using immunoblotting probed with an antibody raised against haptoglobin (Fig 3).  
The molecular weight of this band is anomalous. Haptoglobin usually appears as a band of 
around 20 kDa when strongly reduced and denatured. There have been reports of processed 
haptoglobin forming dimeric and tetrameric complexes when not fully denatured. The buffer 
used was not the classic Laemmli buffer and the samples were not boiled, so there may have 
been interaction between the sub-units. Alternatively, these may be interacting with another 
protein or ligand or these could be splice-variants of the haptoglobin precursor. Further work 
is under way to determine whether this is a robust finding that has broader implications for a 
wider cohort of patients. 
Discussion and Conclusions - Haptoglobin has been implicated in liver disease for some 
time although some contradictory results have been seen. Recently it has been included in a 
panel of tests, the so-called ‘Fibrotest’, which it has been suggested can estimate the degree 
of hepatic fibrosis where serum haptoglobin levels inversely correlate with fibrosis.  
In this study we have shown that in a small number of untreated HCV patients there is a 
reduction of haptoglobin compared to normal plasma. However, during treatment some 
individuals show a dramatic increase in a high molecular weight form of haptoglobin. It is 
unlikely that this is due to any hemolytic events associated with Ribavirin treatment, as this is 
usually associated with reductions in serum haptoglobin. Also, most patients had reasonably 
stable serum hemoglobin during the period of study. In this limited pilot study the patients 
which exhibited an increase in plasma haptoglobin soon after the commencement of IFNα+R 
therapy were those that responded to treatment by reduction of viral load to undetectable 
levels; one albeit transiently. The mechanism of the increase in haptoglobin in response to 
treatment is unknown, and it remains to be seen whether changes in plasma haptoglobin are 
consistently associated with responses to treatment in chronic hepatitis C virus infection. 
Haptoglobin is a positive acute phase reactant and as such plasma levels may be expected to 
be disrupted during periods of inflammation in the liver, although no association with the 
degree of hepatic inflammation has been shown. This of course may have been confounded 
by the negative correlation seen between serum haptoglobin and liver fibrosis. 
Further proteomic analysis of this patient group is ongoing and represents a powerful tool in 
the search for potential biological markers which may help in the management of therapy.    
 
Keywords :  Chronic hepatitis C infection, interferon alpha, ribavirin   
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Introduction 
HCV remains an important cause of liver disease globally and affects over 170 million of 
people worldwide. It has been estimated that about 3–4 million individuals are newly infected 
each year [1]. 
HCV primary infection leads to persistent viremia in 80-85% of cases, and around 60% 
can develop chronicity [2]. Meanwhile, 20% of those reach the end stage of liver disease, 
cirrhosis and /or hepato-cellular carcinoma (HCC) – depending on the variation between 
virus genotypes and subtypes [3-6].  
Currently, treatment with pegylated interferon and ribavirin is the standard of care 
although a number of new drugs are undergoing clinical trials. Non-responsiveness to IFNs is 
fairly common and rates vary in HCV infection [7]. Numerous studies showed that less than 
50% of patients with hepatitis C virus infection respond to IFN-alpha. This ratio is expected 
to increase based on identification of factors that the response to therapy and the likelihood of 
a patient achieving a sustained virological response.  These include HCV genotype, genetic 
variation in the HCV NS5A gene, age, sex, geographic and ethnic group, and host genetics 
[8-15].  
The variation in patient's response to viral therapy has emerged the need to identify other 
markers which allow patients to be stratified as potential non-responders [16, 17].  
Chronic hepatitis C is associated with a largely unexplained iron overload and higher 
oxidative stress. Furthermore, ribavirin treatment leads to higher serum and liver iron levels 
which may due to the haemolytic anaemia induced by ribavirin treatment [18]. 
Proteomic studies of HCV infection have been particularly limited, for several reasons, 
including the lack of a good cell culture model and the need for large amounts of protein for 
conventional proteomic analysis [19, 20]. 
With development in both proteomic methodologies [21, 22], and cell culture models of 
HCV infection [15, 23], it has been made possible to characterize the whole host cell protein 
response within the context of the complete set of HCV genes in vitro.  
Refined multidimensional liquid chromatographic (LC) separations, coupled with mass 
spectrometry (MS) for proteome analysis, have also allowed global experiments to be 
performed, using less protein and obtaining more sensitivity, throughput and dynamic range 
than previous proteomic techniques required [24-26]. 
Liver fibrosis or cirrhosis are considered to be the deleterious consequences of CHC [27-
29] and can be characterized by striking medications of proteins, including synthesis of the 
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extracellular matrix proteins. This in turn suggests that the proteomics may provide a new 
insight in diagnosing fibrosis and cirrhosis [20, 30]. 
Several studies showed by using 2D gel electrophoresis that the expression of more than 
forty proteins could be altered when the cells were activated, either in vivo or in vitro [31, 
32]. 
Surface-enhanced laser desorption/ionization time-of-light mass spectrometry (SELDI-
TOF MS) technology can be applied to obtain the protein quickly and can also perform 
comparative analysis according to the patient’s phenotype. This approach shows the 
advantage of making the first step the fractionation of the proteome according to its adaption 
on different affinity surfaces, followed by adsorption and time-of-light analysis for the 
proteins [33].  
According to a study conducted by Su (2002) on the determination of protein pathways 
and the genomic analyses of liver biopsies from infected chimpanzees, using a sub genomic 
replicon model, the accumulation of the free fatty acids associated with transcriptional 
changes in the host genes involved in lipid metabolism can be determined [34].  
In another study, Jacob (2005) demonstrated that transfection of Huh-7.5 cells with a full-
length HCV replicon induces several protein abundance changes with disturbances in the 
lipid metabolism [31].  
Proteomics and the genome-wide study of protein expression in human beings represent 
an expanding area, and the proteome technology is based on a subtractive procedure, when 
the protein patterns can be compared with the identified markers [35]. 
Proteomic characterization that has been used in human HCC cell lines [27] lead to 
establishing an expanded reference map for human liver tissue and carrying out a differential 
profiling of proteins for normal and tumour tissues of human HCC. Sixteen protein spots 
have been identified and exhibited significant abundance alterations in matched sets of 
normal and HCC tissues and proposed these proteins as candidates for HCC-associated 
proteins.  
The sixteen protein spots corresponded to 11 proteins with a significant abundance of 
normal and tumour tissues, which were identified by using peptide mass fingerprinting. Kim 
et al found that these proteins potentially played a role in the tumour genesis and progression 
of human HCC and were therefore useful markers for diagnostics or targets for therapeutic 
intervention. As a basic tool for the proteome analysis of liver tissues, they expanded a large 
2-DE reference map for human liver tissue [35].  
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In 2009, Mas et al provided important information for elucidating the different steps of 
HCC carcinogenesis, although their findings are limited due to their diagnostic values. Still, 
their identification of non-invasive HCC markers of antigenic proteins showed that these 
markers may be useful in evaluating the HCC patients after therapy, in particular in after liver 
transplantation [32]. 
The human plasma proteome is now promising a revolution in disease diagnosis and 
therapeutic monitoring, since it provides potentially the largest range of the human proteins. 
However, all types of plasma are readily available it is also one of the most difficult protein-
containing samples  to analyses, on account of the large proportion of albumin (55%), the 
wide dynamic range of abundance of other proteins and the tremendous heterogeneity of its 
predominant glycoproteins. In addition, plasma proteins contain all the tissue proteins, such 
as the leakage markers, plus very numerous distinct immunoglobulin sequences [37]. 
Patients and Methods: 
Three patients out of ten chronically infected with Hepatitis C virus who were 
treatment naïve were selected for the pilot study. A written consent form and study 
information sheet were given to each patient. The study was approved by the local research 
ethics committee of Royal Free Hospital. Patients were treated with pegylated Interferon 
alpha dose and Ribavirin dose. Patients were treated for 48 weeks and patients were followed 
up as out-patients where biochemical and virologic parameters were measured and used as 
indicators of response. 
Proteomic analysis 
Peripheral blood samples were taken into EDTA tubes at the start of treatment and again 
at 14 and 28 days. Blood was immediately cooled on ice and within 15 minutes centrifuged at 
5000 RPM for 10 minutes to separate the plasma which was aliquoted and stored at-80°C The 
plasma was then depleted of albumin and IgG using the Bio-Rad Aurum Serum protein mint 
kit which removes over 90% of the total albumin and immunoglobin, effectively enriching 
the other plasma proteins and maximising their resolution by electrophoresis. Protein 
concentration of the depleted plasma was then measured using the Bradford assay. 
2D gel electrophoresis was performed on selected samples using GE Healthcare IPGphor 
IEF and Ettan units according to the manufacturer’s instructions. Briefly, 70 ug depleted 
plasma protein was mixed with Sample Buffer (8M urea, 4% CHAPS; 2% Ampholytes; 50 
mM DTT; 0.001% Pyronin Y) and rehydrated into immobilized pH Gradient (iPG) strips 
overnight (5-8 pH range). Iso-electric focusing was carried out and the IPG strips were then 
European Scientific Journal    November edition vol. 8, No.27   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
8 
 
equilibrated into Loading Buffer (BM Urea, 50 mM Tns, 2% Lauryl SDS, 0.001% Pyronin Y, 
pH 6.8) and reduced with 50 mM DTT, prior to alkylation with 20 mM iodoacetamide.  
The IPG strips then run onto a 12% polyacrylamide gel for SDS-PAGE. The gels are then 
washed briefly and stained with Colloidal Coomassie Blue. The gels were destained in water 
and imaged using a BioRad GS- 800 Scanning Densitometer and PDQuest software. 
Western blotting 
10 ug samples of plasma for 1D SDS-PAGE were then added to four-times the 
volume of loading buffer. Samples were kept cool and then electrophoresed through a 12% 
SDS-PAGE gel. The gels then either stained with Colloidal Blue and imaged, or electro-
blotted onto PVDF membranes. The membrane was blocked with 5% milk powder and then 
probed with mouse monoclonal antibody to human haptoglobin (Sigma H6395). The 
membrane was then washed thoroughly with PBS/Tween, incubated with antibody to mouse 
immunoglobulin’s-HRP (Dako P0260) and washed again with PBS/Tween. The membrane 
was developed using ECL plus (OF Healthcare) and the image acquired on a BioRad Fluor-S 
multi-imager KOa O 14 21. Spots and bands were excised from the polyacrylamide gels and 
dried under vacuum. Proteins were digested using trypsin in 30 mM Ammonium Bicarbonate. 
The samples were concentrated under vacuum and extracted using a mixture of acetonitrile 
and 0.1% Formic Acid. Tandem mass spectrometry data were then analysed using the Mascot 
programme (Matrix Science). 
Results 
Characteristics of patients 
The study included 10 patients infected with HCV. There were 3 male and 7 female 
patients. Male patients were 1 TR, 1 NR and 1R. Female patients were 2 TR, 3 NR and 2 R 
(table 1).  
Table1: Frequency by sex of responders and non-responders for HCV treatment 
 
 
Name 
 
 
Sex Sample date 
Date 
of treatment 
Kind 
of 
Respond 
Over all 
samples 
# 
Pt1 
 
 
M 
 
15/10/2001 15/10/2001 TR 1 
05/11/2001 2 
01/12/2001 3 
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Pt2 
 
 
M 17/01/2000 17/01/2000 NR 4 
22/08/2000 5 
14/12/2000 6 
Pt3 
 
 
F 28/11/2001 28/11/2001 TR 7 
13/03/2002 8 
27/03/2002 9 
Pt4 
 
 
F 08/08/2001 16/03/2001 R 10 
12/09/2001 11 
20/09/2001 12 
Pt5 
 
 
F 20/09/2001 20/09/2001 TR 13 
24/10/2001 14 
22/11/2001 15 
Pt6 
 
 
F 26/04/2000 02/10/2001 NR 16 
05/10/2001 17 
14/11/2001 18 
Pt7 
 
 
F 05/02/2001 05/02/2001 R 19 
07/03/2001 20 
04/04/2001 21 
Pt8 
 
 
F 17/01/2000 20/01/2000 NR 22 
23/08/2000 23 
17/11/2000 24 
Pt9 
 
 
M 20/09/2006 20/09/2006 R 25 
25/10/2006 26 
21/12/2006 27 
Pt10 
 
 
F 17/09/2006 17/09/2006 NR 28 
21/10/2006 29 
18/12/2006 30 
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Proteomic Results 
The patients plasma were run on the SDS-PAGE of the time into treatment, and (figure 1) 
shows the transient responder and the non-responder all with the responder which framed in a 
red dotted boxes in order to show the Hp band which identified by the LC-MS/MS.  
 
Figure 1. Patient plasma samples run on SDS-PAGE. Time into treatment at which sample take shown 
along the top in days. TR-transient responder, NR=non-responder, R=responder. Red dotted boxes show 
the haptoglobin bands identified by LC-MS/MS. 
A western blotting (WB) analysis for the patients plasma were examined by the mouse 
monoclonal Ab to human Hp in the time during treatment. At (figure 2 A-C) the 80KDa of 
Hp band are framed in red dotted boxes and run on 1D gel. 
 
Figure 2. Western blot analysis of patient plasma samples stained with mouse monoclonal antibody to 
human haptoglobin. Time into treatment shown along the top in days. ~80kDa haptoglobin identified by 
red dotted boxes. 
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When the plasma was analyzed using 2D electrophoresis, a number of differences were 
seen in patients compared to the controls. Perhaps the most striking being the absence of 
haptoglobin alpha chain forms which were identified by electrospray mass spectrometry 
(figure 3). 
 
Figure 1. Representative 2D gel images of normal and hepatitis C virus infected plasma (a) normal (b) 
hepatitis C. Red ellipses identify Haptoglobin alpha chain 
Further analysis of albumin-depleted plasma by 1D SDS-PAGE found that two of the 
patients showed a considerable increase in an approximately 80 kDa protein band in samples 
taken at days 14 and 28 on treatment when compared with a pre-treatment sample.   
This protein was identified as deriving from the haptoglobin precursor using LC-MS/MS. 
The patients who exhibited the increase in the ~80 kDa protein were a responder and a 
transient responder to treatment.  
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The patient who did not respond to treatment showed no temporal increase in this protein 
in responders which was confirmed by using immunoblotting probed with an antibody raised 
against haptoglobin. 
Discussion 
In this study we have shown that in a small number of untreated HCV patients there is a 
reduction of haptoglobin compared to normal plasma. However, during treatment some 
individuals show a dramatic increase in a high molecular weight form of haptoglobin.  
In this limited pilot study the patients which exhibited an increase in plasma haptoglobin 
soon after the commencement of IFNα+R therapy were those that responded to treatment by 
reduction of viral load to undetectable levels; one albeit transiently.  
It is unlikely that this is due to any haemolytic events associated with Ribavirin treatment, 
as this is usually associated with reductions in serum haptoglobin. Also, most patients had 
reasonably stable serum hemoglobin during the period of study.  
Haptoglobin is a positive acute phase reactant and as such plasma levels may be expected 
to be disrupted during periods of inflammation in the liver, although no association with the 
degree of hepatic inflammation has been shown. This of course may have been confounded 
by the negative correlation seen between serum haptoglobin and liver fibrosis. 
Haptoglobin has been implicated in liver disease for some time although some 
contradictory results have been seen. Recently it has been included in a panel of tests, the so-
called ‘Fibrotest’, which it has been suggested can estimate the degree of hepatic fibrosis 
where serum haptoglobin levels inversely correlate with fibrosis. 
The mechanism of the increase in haptoglobin in response to treatment is unknown, and it 
remains to be seen whether changes in plasma haptoglobin are consistently associated with 
responses to treatment in chronic hepatitis C virus infection.  
Further proteomic analysis of this patient group is ongoing and represents a powerful tool 
in the search for potential biological markers which may help in the management of therapy.      
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